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This issue of *Critical Care*features an article on the outcome of patients with posttraumatic intracranial lesions after head trauma and a positive history of pre-injury antiplatelet medication intake by Andrea Fabbri and colleagues from the Italian Society of Emergency Medicine \[[@B1]\]. Due to the high prevalence of cardiovascular diseases, the results of this study are of high interest to a broad audience from primary care to emergency departments and specialized neurotraumatological centres. Within the last decades, traumatic brain injury (TBI) has increasingly been recognized not only as \'the leading cause of mortality among patients under 45 years of age\', but also as a growing disease in the ageing population of industrialized countries. Antiplatelet therapy is common in this population and has been associated with increased morbidity and mortality after head injury, but the evidence has been based mainly on pathophysiologic rationales and retrospective analyses with limited patient numbers \[[@B2]\]. Nevertheless, in some centres the scarce evidence available has led to protocols involving transfusion of platelet concentrates and administration of haemostatic substances for TBI patients with pre-injury use of antiplatelet medication. But are TBI patients really at increased risk for an unfavourable outcome if they have been treated with antiplatelet agents prior to injury?

The present study by Fabbri and colleagues adds important information to this discussion. The authors have to be applauded for the high total number of analysed patients with pre-injury intake of antiplatelet medication and posttraumatic intracranial lesions after head trauma. The number of 537 subjects, enabled by the multicentric study design with 32 participating centres, exceeds the total number of a recent meta-analysis of available studies on this topic \[[@B3]\] and allows conclusive statistical analyses. In this study, pre-injury intake of antiplatelet medication doubled the risk of lesion progression on computed tomography scans within 24 hours after trauma. Moreover, the risk of an unfavourable outcome on the Glasgow Outcome Scale 6 months after injury was increased by 50% in patients with pre-injury antiplatelet therapy.

What consequences should be drawn by the findings of this study? Appealing to primary care physicians for a more rational use of antiplatelet medication? More likely, optimizing current prescription practices and patient compliance would lead to even more patients treated with antiplatelet agents \[[@B4]\]. The present study demonstrates that if head injury results in posttraumatic intracranial lesions, these patients are at an increased risk for haematoma progression and an unfavourable outcome. This corresponds well with findings of Major and Reed \[[@B5]\], who observed a mortality rate of 21% in a study on patients with aspirin intake and posttraumatic intracranial haemorrhage. Clinicians must be aware of this increased risk profile and should adapt thresholds for clinical observation and repeated cranial imaging studies for respective patients. Routine application of haemostatic substances or transfusion of platelet concentrates cannot be recommended on the basis of available evidence \[[@B2]\]: still there is equipoise, whether counteracting antiplatelet therapy in the acute phase after TBI should be undertaken or not.

Increased bleeding tendencies may cause haematoma enlargement with concomitant mass effect on surrounding brain tissue. In the present study, antiplatelet therapy with aspirin and clopidogrel increased the risk of haematoma enlargement as well as the need for neurosurgical intervention. On the other hand, a recent study on 839 severely injured blunt trauma patients revealed that pre-injury treatment with antiplatelet agents reduced the risk of lung dysfunction and multi-organ failure if packed red blood cells were transfused \[[@B6]\]. Patients with severe TBI were excluded from data analysis in this study, but experimental studies have attributed several neuroprotective properties to aspirin \[[@B7]\]. Antiplatelet therapy in aneurysmal subarachnoid haemorrhage is associated with a trend towards better outcome in patients, possibly due to a reduced incidence of delayed cerebral ischaemia \[[@B8]\]. Coagulopathy after TBI is a dynamic process involving increased bleeding tendency as well as hypercoagulability leading to cerebral microthrombosis \[[@B9]\]. Posttraumatic cerebral microthrombosis, largely generated by platelet activation \[[@B10]\], may cause secondary brain injury due to cerebral hypoperfusion and ischaemia. Theoretically, antiplatelet therapy may also exert neuroprotective effects regarding the cerebral microcirculation after TBI. Nevertheless, in light of the available data, and in particular from the present study, it has to be assumed that in the acute phase after trauma, neuroprotective effects of antiplatelet therapy on the microcirculation are outweighed if computed tomography reveals posttraumatic intracranial lesions in patients. Further studies on the role of antiplatelet therapy in trauma and TBI are needed to optimize tomorrow\'s treatment protocols.
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